Welcome to InVasc Therapeutics
Developing first-in-class drugs for the cardiometabolic market.
InVasc is a clinical stage biopharmaceutical company developing drugs to treat or prevent chronic kidney and cardiometabolic diseases. We are currently focused on advancing our lead drug for Chronic Kidney Disease (CKD) through Phase II development. CKD, cardiovascular and metabolic diseases are the leading causes of morbidity and mortality worldwide and collectively represent the largest global markets for pharmaceutical drug development.